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LIST OF ABBREVIATIONS USED IN THE PROFORMA, 
MASTER CHART AND IN THE DISSERTATION 
HIV               HUMAN IMMUNODEFICIENCY VIRUS 
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ATT              ANTI TUBERCULOUS TREATMENT 
ART             ANTI RETROVIRAL THERAPY 
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M                 MALE 
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DC              DIFFERENTIAL COUNT 
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WHO         WORLD HEALTH ORGANISATION 
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INTRODUCTION 
Tuberculosis is a major public health problem in many of the 
developing countries. This is further complicated by the HIV infection, 
which is a pandemic disease and also leads to the emergence of the 
multidrug resistant tuberculosis strains. WHO has declared tuberculosis 
as a global emergency in 1993 and the member nations adopt various 
control programmes to control the disease. 
(1) 
HIV infection cause progressive immunodeficiency state, 
rendering the infected persons to increased susceptibility to various 
opportunistic infections, as the immune system becomes less able to 
prevent the growth and spread of the disease. Of these various 
opportunistic infections Tuberculosis is the most common disease. 
Mycobacterium tuberculosis infects one third of the world’s 
population. Worldwide there are about 8 million new cases and 3 million 
deaths every year. Of the majority of the cases and deaths occur in 
developing countries. 
India has the largest number of tuberculosis (TB) cases in the 
world. India has 14 million cases of TB and it is estimated that about 1.8 
million incident cases of TB occur in India every year. 
(2) 
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Individuals infected with M. tuberculosis have an approximately 
10% life time risk of developing active TB, whereas the persons infected 
with HIV have 10% annual risk of getting infected with tuberculosis. 
Conversely Mycobacterium tuberculosis accelerates the progression of 
the HIV infection. 
(3) 
Hence it is essential to treat tuberculosis effectively in persons 
with HIV infection and reducing the mortality of these persons. 
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OBJECTIVES OF THE STUDY 
 
1. To evaluate the clinical, bacteriological and radiological pattern of                                                        
tuberculosis infection among HIV seropositive individuals in 
correlation with the CD 4+ counts. 
 
2. To find out the pattern of Tuberculosis infection, in HIV 
seropositive patients attending Coimbatore medical college 
hospital. 
 
3. To find the prevalence of Pulmonary Tuberculosis among HIV 
Seropositive patients attending Coimbatore Medical College 
hospital.  
 
4. To find the correlation between the manifestations of pulmonary 
tuberculosis and the CD4 count at the time of diagnosis of 
pulmonary tuberculosis. 
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REVIEW OF LITERATURE 
 
TUBERCULOSIS   
     is an ancient disease  caused by the organism Mycobacterium 
tuberculosis .It was first discovered  by Robert Koch in 1882.  It is 
slightly curved or straight bacilli of size 0.2 to 0.6 by 1.0 to 10 microns. 
(4)
 Tuberculosis is also caused by Mycobacterium bovis and 
Mycobacterium africanum occasionally. These bacteria are also known as 
tubercle bacilli or acid fast bacilli (AFB). 
(5)
  
 
M. tuberculosis infects a third of the world's population. In 2000 
there were an estimated 8.3 million new cases of TB worldwide. 95% of 
TB cases and 98% of TB deaths are in developing countries. 75% of TB 
cases in developing countries are in the economically productive age 
group (15–50 years).There was 1.8 million deaths from TB in 2000, with 
2, 26,000 cases attributable to HIV (12%).TB deaths comprise 25% of all 
avoidable adult deaths in developing countries. India alone is estimated to 
have 5.1 million PLWH. Every year, 1.8 million TB cases are notified 
and treated under DOTS in India. Between 2.5 to 3 million people in the 
Region are currently estimated to be infected with both HIV and TB 
(6).
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The bacterium has high lipid content in the cell wall which 
includes mycolic acid, which is not readily stained with Gram stain. 
Hence special staining techniques are required to promote the uptake of 
the stain. Hence acid-fast detection techniques are used. The bacterium is 
detected by Ziehl-Neelsen staining method or by Fluochrome staining 
methods using auramine or auramine-rhodamine fluorescein stains.  The 
bacteria grow well in Lowenstein- Jensen medium with incubation period 
of two to five weeks.  
Mycobacterium tuberculosis is an obligate aerobe. For this reason, 
in the classic case of tuberculosis, MTB complexes are always found in 
the well-aerated upper lobes of the lungs. The bacterium is a facultative 
intracellular parasite, usually of macrophages, and has a slow generation 
time, 15-20 hours, a physiological characteristic that may contribute to its 
virulence. 
The Tuberculosis genome was sequenced in 1998. Its size is 4 
million base pairs, with 3959 genes. The genome contains 250 genes 
involved in fatty acid metabolism, with 39 of these involved in the 
polyketide metabolism generating the waxy coat. Such large numbers of 
conserved genes shows the evolutionary importance of the waxy coat to 
pathogen survival.  
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SOURCE OF INFECTION: 
 
The most important source of infection is the tiny infectious 
droplet nuclei coughed out by the infected patient. A single cough can 
produce 3000 droplet nuclei. Droplet nuclei also spread by talking, 
sneezing, spitting and singing, and can remain suspended in the air for 
long periods. Direct sunlight kills the tubercle bacilli in 5 minutes, but 
they can survive in the dark for long periods. Transmission therefore 
generally occurs indoors. Droplet nuclei are so small that they avoid the 
defense of the bronchi and penetrate into the terminal alveoli of the lungs, 
where multiplication and infection begin. Two factors determine an 
individual's risk of exposure: the concentration of droplet nuclei in 
contaminated air and the length of time he or she breathes that air. The 
infected persons develop the disease at any time. The disease affects 
almost all organs of the body, lung being the most commonly affected. 
The most important trigger for the progression from infection to disease 
is the weakening of the immune resistance as in HIV infection. If 
untreated 50% patients die, 25% live healthy and 25 % will remain ill 
with chronic infectious TB. 
PATHOGENESIS 
Primary infection: 
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     This occurs in persons not exposed to the bacilli previously. Here the 
bacilli are deposited in the terminal bronchiole and the alveoli, wherein 
they develop the Ghons focus, with lymphatic spread develop the Ghons 
complex. Then the infection might spread to all over the body later. Here 
the immunity develops in  
4 to 6 weeks period (delayed hypersensitivity and cellular 
immunity). In most cases due to this immunity the bacilli either stops 
multiplying or may remain as dormant bacilli the body itself. 
 
Post primary infection: 
     This occurs after months to years after the primary infection. Here 
there is either reactivation of the dormant bacilli or reinfection.  
The CD4 cells which are MHC class II restricted CD4 
lymphocytes, play a key role in the immune response against 
tuberculosis, as they produce IFN gamma and activating cytokines which 
are necessary to contain the infection. 
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CLINICAL FEATURES OF TUBERCULOSIS 
(7)
 
Primary infection: 
May cause   
1. No clinical disease. 
2. Positive tuberculin test. 
3. Hypersensitivity reactions like erythema nodosum, phylecten etc. 
4. Pulmonary/ pleural -  pneumonia , consolidation, collapse, effusion. 
5. disseminated disease like military TB, meningitis, pericarditis,   
lymphadenopathy.  
 
Post primary infection: 
May cause   
1. Pulmonary TB as cavities, infiltrates, progressive pneumonia, 
endobronchial TB. 
2. Extrapulmonary as pleural effusion, lymphadenopathy , meningitis, 
tuberculoma, GI TB, genital tract TB, renal , adrenal TB and skin 
manifestations .  
Clinical symptoms needed for the diagnosis of the Pulmonary 
tuberculosis are: 
Cough for more than 3 weeks, 
Sputum production, 
Weight loss. 
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 Other symptoms are chest pain, hemoptysis  and dyspnoea, along 
with constitutional symptoms of fever, night sweats, tiredness, loss of 
apetitite etc. 
Physical signs are not disease specific for tuberculosis. They do 
not help to differentiate from other respiratory infections. 
 
INVESTIGATIONS 
SPUTUM AFB: Two samples of early morning sputum for Zeihl – 
neelson staining.  
Chest radiograph to diagnose the sputum negative cases may show 
classically infiltrations in upper zones, cavities in upper zones and 
atypically the interstitial infiltration, lymphadenopathy, pleural effusion 
etc. 
CULTURE OF THE M. tuberculosis
 (8)
 done using LJ medium. This is 
gold standard test for the diagnosis of Tuberculosis. But it takes more 
than 8 weeks for the bacilli to be cultured and needs culture facility and 
laboratory skills. Hence not readily available and cannot be done 
regularly.  
Other methods are  
BACTEC 460 TB system 
ESP Culture II System 
BacT/Alert MB  
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MGIT tube system 
Chromatographic identification 
Identification by nucleic acid probes 
Molecular methods like AMTD test, Roche 
Amplicor M.TB test based on PCR assay. 
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MYCOBACTERIUM TUBERCULOSIS – OIL IMMERSION VIEW 
 
 
 
MYCOBACTERIUM  TUBERCULOSIS  - ELECTRON  
MICROSCOPIC VIEW 
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HUMAN IMMUNODEFICIENCY VIRUS 
    First discovered by Luc Montaineger in 1983, named as 
LAV 2, simultaneously Robert Gallo discovered in 1984, named as 
HTLV III. Both were later found to be the same virus, hence was 
redesignated as HIV by the International Committee on taxonomy of 
viruses. A variant of this HIV was identified at western Africa, hence the 
former was known as HIV 1 and the latter as   HIV 2. A similar virus is 
reported in African green monkeys, named SIV (Simian 
Immunideficiency Virus)
 (9). 
 
      HIV virus belongs to the class Retroviruses and family 
Lentivirinae. It has an outer envelope of lipid bilayer with uniformly 
arranged 72 spikes or knobs gp120 and gp 41. It has a single stranded 
RNA virus in its core along with enzymes reverse transcriptase, integrase 
and protease, all needed for viral replication and maturation. Surrounding 
this is P17 core Gag protein, which is needed to maintain the integrity of 
the viral particle. The size of the genome is 9 kb.  
 
     As the virus enters the blood stream, it binds to CD4 
receptor on the T lymphocyte via the gp 120 cover, enters the cell 
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cytoplasm, uncoats its envelope, and sheds the viral RNA and the enzyme 
reverse transcriptase.  
This enzyme facilitates    conversion of viral RNA to DNA- 
pro viral DNA. This then creates its mirror image using the enzyme 
integrase. This then unites with the host genome becomes its integral part. 
It multiplies repeatedly, produces m RNA along with multiplication of 
the host nucleus. The mRNA directs the host cells to produce the new 
viral particles with the help of the enzyme protease. This small virions 
bud out of the host cell to infect another host cell. During the active 
replication stage around one billion viruses are produced daily. 
     HIV virus is very fragile. It is inactivated at temp of 56C for 
30 mins or boiling for few seconds. Also inactivated by 0.2%sodium 
hypochlorite, 2%glutaraldehyde, 70%ethanol,  betapropiolactone etc. 
The virus is transmitted by sexual intercourse, blood 
transfusion, perinatal transmission, IV drug abuse – sharing of infected 
needles, needle stick injuries etc.  
     HIV virus cause progressive impairment of cellular immune 
response, decline in the CD4 count increased susceptibility to 
opportunistic infections and certain malignancies also. The disease 
progresses as  
1. Typical progressors with mean survival time of 10 years,  
2. Rapid progressors with mean survival time of 3-4 years and  
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3. Long term non progressors who do not experience the HIV disease.  
 
Revised World Health Organization (WHO) Clinical Staging of 
HIV/AIDS for Adults and Adolescents (2005)  
Primary HIV infection 
• Asymptomatic 
• Acute retroviral syndrome 
Clinical stage 1 
• Asymptomatic 
• Persistent generalized lymphadenopathy 
Clinical stage 2 
• Moderate and unexplained weight loss (<10% of presumed or 
measured body weight) 
• Recurrent respiratory tract infections (such as sinusitis, bronchitis, 
otitis media, pharyngitis) 
• Herpes zoster 
• Recurrent oral ulcerations 
• Papular pruritic eruptions 
• Angular cheilitis 
• Seborrhoeic dermatitis 
• Fungal finger nail infections 
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Clinical stage 3 
Conditions where a presumptive diagnosis can be made on the basis of 
clinical signs or simple investigations 
• Unexplained chronic diarrhea for longer than one month 
• Unexplained persistent fever (intermittent or constant for longer 
than one month) 
• Severe weight loss (>10% of presumed or measured body weight) 
• Oral candidiasis 
• Oral hairy leukoplakia 
• Pulmonary tuberculosis (TB) diagnosed in last two years 
• Severe presumed bacterial infections (e.g. pneumonia, empyema, 
meningitis, bacteraemia, pyomyositis, bone or joint infection) 
• Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis 
Conditions where confirmatory diagnostic testing is necessary 
• Unexplained anaemia (< 80 g/l), and or neutropenia (<500/µl) and 
or thrombocytopenia (<50 000/ µl) for more than one month 
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Clinical stage 4 
Conditions where a presumptive diagnosis can be made on the basis of 
clinical signs or simple investigations 
• HIV wasting syndrome 
• Pneumocystis pneumonia 
• Recurrent severe or radiological bacterial pneumonia 
• Chronic herpes simplex infection (orolabial, genital or anorectal of 
more than one month’s duration) 
• Oesophageal candidiasis 
• Extrapulmonary Tuberculosis 
• Kaposi’s sarcoma 
• Central nervous system toxoplasmosis 
• HIV encephalopathy 
Conditions where confirmatory diagnostic testing is necessary 
• Extrapulmonary cryptococcosis including meningitis 
• Disseminated non-tuberculous mycobacteria infection 
• Progressive multifocal leukoencephalopathy 
• Candida of trachea, bronchi or lungs 
• Cryptosporidiosis 
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• Isosporiasis 
• Visceral herpes simplex infection 
• Cytomegalovirus (CMV) infection (retinitis or of an organ other 
than liver, spleen or lymph nodes) 
• Any disseminated mycosis (e.g. histoplasmosis, coccidiomycosis, 
penicilliosis) 
• Recurrent non-typhoidal salmonella septicaemia 
• Lymphoma (cerebral or B cell non-Hodgkin) 
• Invasive cervical carcinoma 
• Visceral leishmaniasis 
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DIAGNOSIS 
Is by   
1. EIA - enzyme immune assay, good screening test, sessitivity > 99.5% 
2. Western blot – mostly commonly used confirmatory test. 
3. Direct detection test – p 24 antigen capture assay. 
4. RT PCR-to detect the HIV RNA. 
MONITORING of the patients’ infection is by CD4 count  It is the 
best indicator of the immediate state of immunologic competence of the 
patient. If < 350 anti retroviral therapy (ART) to be initiated, if < 200, 
PCP prophylaxis to be started, if < 50. Prophylaxis against MAC to be 
started.  
Other means are by HIV RNA measurement in the serum or 
plasma. 
(10).
 
 
 
 
 
 HIV VIRUS 
 
 
CD 4 CELL A DIAGRAMATIC REPESENTATION
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– A DIAGRAMATIC REPRESENTATION
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HIV RELATED TB 
By the end of 2000, 11.5 million HIV infected people were 
coinfected with M .tuberculosis worldwide. 70% were in sub Saharan 
Africa, 20% in South East Asia and 4% in Latin America and Caribbean 
(11)
according to WHO, 39% of the Tuberculosis cases are seen in South 
East Asia, of these, 95 % cases are reported from India, Indonesia, 
Myanmar and Thailand.
(12). 
Tuberculosis has a lifetime risk of infection of 10% in non HIV 
population, whereas in HIV infected it carries a annual risk of 10% every 
year, which means HIV patients have 10 times the risk of developing the 
TB than the non HIV patients. This is by means of either reactivation of 
the latent TB infection by immunosuppression or by reinfection with 
MTB. HIV does not enhance the infectiousness of the individual patients 
with TB. 
Conversely MTB induces progression of the HIV 
immunosuppression by inducing the replication if HIV in cells of the 
monocyte lineage by TNF alpha and various chemokines and by 
activation of latent HIV in alveolar macrophages or in monocytes. The 
viral load increases by 2.5 fold at the diagnosis of TB. This may also 
explain the low CD4 count in the HIV patients who are on HAAT 
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diagnosed to have tuberculous infection   during   their course of 
treatment for HIV disease. Thus there is a complex immunological 
interaction of HIV and TB infection 
(13)
 leading to progression of both the 
infections.  
The pattern of the HIV related TB  is that , due to 
immunosuppression , the immune system is unable to prevent the growth 
and local spread of the tuberculosis; hence more immunosuppression, 
more the disseminated and extrapulmonary TB. Even in HIV infected 
persons pulmonary tuberculosis is the most common presentation. But its 
presentation varies with the disease activity.  
In early HIV disease, the clinical picture resembles post primary 
PTB, sputum AFB is often positive and X ray shows cavities. Whereas in 
late HIV disease, the clinical picture resembles that of primary PTB, 
sputum AFB is often negative, and X ray shows often infiltrates rather 
than cavities.
  (14)
  
In HIV-infected patients with pulmonary TB, cultures are positive 
in about 90% of cases and sputum smears are positive in about 50% to 
70%--numbers that are similar to those seen in immunocompetent adults 
with reactivation TB 
(15).
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 Latent Tuberculosis Infection (LTBI) 
Screening for latent tuberculosis infection (LTBI) is an essential 
step in controlling the spread of tuberculosis. Screening for LTBI is 
recommended in persons at risk for recent infection and in those groups 
with increased risk of progression to active disease once infected, 
including HIV-infected persons. The tuberculin skin test using 1 TU 
(Tuberculin unit) – Mantoux test, is currently the only method available 
for identifying LTBI. Routine annual tuberculin skin testing is 
recommended in HIV-infected individuals. 
A reaction of >5 mm induration is considered positive for HIV-
infected patients and persons with other forms of severe 
immunosuppression, persons who are close contacts of infectious cases, 
and persons with abnormal chest radiographs consistent with 
tuberculosis
(16).
  Use of the 5-mm cutoff is supported by a prospective 
study in the United States demonstrating that the risk of tuberculosis was 
significantly higher in HIV-infected persons with tuberculin skin test 
reactions >5 mm of induration than in those who have a reaction <5 
mm
.(17).
  
 It is important to keep in mind that a negative tuberculin skin test 
does not exclude infection or active disease. Testing with tuberculin 
purified protein derivative is dependent on the presence of an intact cell-
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mediated immune response. In the setting of HIV infection, reduced cell-
mediated immunity can lead to decreased delayed-type hypersensitivity 
(DTH) responsiveness, resulting in False-negative skin tests. In a 
multicenter study in the United States, the prevalence of a positive 
tuberculin skin test (>5 mm) was shown to decrease with decreasing CD4 
T-cell counts.
 (18)
 
The Threat of Drug Resistance 
 
If a TB drug regimen is not completed or is taken sporadically, TB 
bacteria can develop resistance to the drugs, so the drugs are no longer 
effective at killing the bacteria. People with HIV/AIDS are at even 
greater risk for developing drug-resistance because they may not absorb 
the medicines as well as others. Also, because their immune system is 
damaged, it is unable to help the TB medicines get rid of the TB bacteria. 
The threat of active tuberculosis, including drug resistant TB, continues 
for HIV patients, even after they are successfully managed on HIV 
antiretroviral therapy. 
Multidrug-resistant TB (MDR TB) can develop when bacteria 
become resistant to the two most powerful first line drugs (isoniazid and 
rifampicin). When this happens, second-line drugs are required, which are 
more expensive and have more side effects. 
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Extensively drug-resistant TB (XDR TB) can develop when 
second-line therapies are not used properly and the, bacteria develop 
resistance to them as well. Treatment options are extremely limited for 
people with XDR TB and the risk of death is extremely high—
particularly for people living with HIV/TB.
 (19) 
 
TREATMENT OF TUBERCULOSIS AND HIV DISEASE 
TREATMENT OF TUBERCULOSIS 
Category of 
Treatment 
Type of patient Regimen 
Sputum 
Examination 
CAT-I New sputum smear 
positive/ negative 
Seriously ill / not 
seriously ill sputum-
negative 
Seriously –ill/ not 
seriously ill EP 
2 H3R3Z3E3/ 
4 H3R3 
0  2  4    6 
      3    5    7 
MONTHS 
CAT- II Sputum smear +  
Relapse, Failure, 
Treatment after 
Default  
3 H3R3Z3E3S3/ 
1 H3R3Z3E3/ 
5 H3R3E3. 
0  3   5    8 
      4    6      9 
    
    In the latest RNTCP guidelines 2010, the Category III has been 
removed; instead the cases are treated with Category I.  
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WHO recommendations for the treatment of TB and HIV co infection 
with reference to CD-4 cell count. 
CD 4 cell count Recommended regimen Comments 
< 200 mm
3
 Start TB treatment. Start 
ART as soon as TB 
treatment is tolerated (2 
weeks to 2 months) 
EFV containing 
regimens. 
Recommended ART 
EFV is contraindicated in 
pregnant or women of 
childbearing potential 
without effective 
contraception 
200 to 350 mm
3
 Start TB treatment. start 
one of the below 
regimens after initiation 
phase: EFV containing 
regimens or NVP 
containing regimens in 
case of Rifampicin free 
continuation phase TB 
treatment regimen. 
Consider ART 
> 350 mm
3 
 
Start TB treatment. 
 
Defer ART 
 
CD 4 count not available 
 
Start TB treatment. Consider ART 
 
The WHO recommended treatment regimen - 2010 for HIV and PTB co-
infection is  
 
AZT or TDF + 3TC   ( zidovudine +tinofovir+ lamivudine) or  
 
FTC + EFV ( emtricitabine+ efavirenz) 
 
Initiate ART as soon as possible (within the first 8 weeks) after starting 
TB treatment. 
 
NVP or triple NRTIs are acceptable options if EFV 
cannot be used( nvp – nivirapine)  
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Abbreviations: 
. AZT- zidovudine, TDF- tinofovir,  
3TC- lamivudine, FTC- emtricitabine ,  
EFV- efavirenz, NVP- nevirapine, 
NRTI-  nucleoide reverse transcriptase inhibitor. 
 
PARADOXICAL REACTION 
Is defined as a temporary exacerbation of symptoms, signs and 
radiological manifestations of TB after days to weeks of ATT. This is 
seen in patients with TB adenitis without HIV infection. And it is seen 
more so in HIV infected persons that too more in those on HAART. The 
immune reconstitution response is the likely explanation for this. It is 
generally self limiting in 10 to 14 days, rarely if the reaction is very 
severe, then HAART may be stopped temporarily and corticosteroids 
may be started. 
(20, 21)
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MATERIALS AND METHODS 
 
Methodology 
This study was conducted from March 2010 to October 2010, at 
Coimbatore Medical College Hospital, Coimbatore. 
 
Two sets of patients were selected for the study. 
1. Patients attending the OP departments of Medicine and Thoracic 
Medicine or patients who were admitted at the Medical wards with  
symptoms suggestive of Pulmonary tuberculosis, ( cough of more 
than three weeks duration, fever, hemoptysis, loss of weight etc)  
were screened for Pulmonary Tuberculosis with Chest X Ray 
investigation and Two samples of Sputum AFB. If these patients 
were found positive for pulmonary tuberculosis, they were 
screened for HIV disease at the ICTC centre. 
(22)
    If found 
positive, they were included in the study with the consent of the 
patient.  
Screening for HIV disease was done by the ELISA Rapid 
diagnostic tests 
a. Combiaids 
b. Instachek 
c. Acon Biotech. 
45 
 
If one test was positive, the remaining other two tests were 
performed and if found positive, the diagnosis of HIV was made 
as per the guidelines.  
2. HIV positive patients who were either under observation or under 
HAART, who developed symptoms and signs suggestive of 
Pulmonary Tuberculosis were screened for the same; if found 
positive for Pulmonary tuberculosis , they were included in the 
study after obtaining their consent. 
These patients were investigated as following: 
a. Chest X - Ray PA view, if needed Lateral view (if not done 
earlier). 
b. Sputum for AFB two early morning samples (if not done 
earlier). 
c. Blood hemoglobin, total count differential count, Erythrocyte 
sedimentation rate, sugar, urea 
d. Serum creatinine, Liver function test.  
e. CD4 count 
The chest X -ray was taken by digital imaging, read by a 
general physician, chest physician and a radiologist to diagnose 
pulmonary tuberculosis. 
The blood investigations were done by conventional methods. 
Sputum AFB was done by ZIEHL NEELSON method. 
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CD4 count was done by the PARTEC CYFLOW COUNTER 
(flow cytometer). 
 
INCLUSION CRITERIA: 
Patients with symptoms of pulmonary tuberculosis, who were 
confirmed with the diagnosis of Pulmonary tuberculosis - both 
Sputum AFB positive and Sputum AFB negative (diagnosed 
radiologically). 
Patients with Tuberculous Pleural Effusion were included in the 
study. 
 
EXCLUSION CRITERIA: 
1. Patients who were suffering from Extra-pulmonary Tuberculosis 
infections like TB Pericarditis, TB meningitis, TB Abdomen, 
isolated TB lymphadenopathy, Potts Spine and other seriously ill 
patients. 
2. Patients found to have positivity in only one of the three ELISA 
tests for HIV. 
3. No consensus among all the three independent observers regarding 
the  X-Ray features of Pulmonary Tuberculosis. 
4. Patients suspected or confirmed Latent Tuberculosis 
Infection(LTBI). 
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STUDY LIMITATIONS: 
The confirmation of HIV infection could not be done by Western 
Blot analysis. 
The sputum positivity for tuberculosis could not be confirmed by 
AFB culture as the procedure was expensive, needed technical experience 
and also was not available at this hospital.  
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OBSERVATIONS AND RESULTS 
 
 
 
 
 
 
 
 
 
 
 
 
 OBSERVATIONS AND RESULTS
The study was done during a 
2010 at Coimbatore Medical College Hospital, out of 707 HIV positive 
patients, 59 cases were diagnosed as pulmonary tuberculosis which 
included pleural effusion also.
 
Number of HIV positive cases observed from
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period from March 2010 to October 
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  Out of the707 HIV positive cases, 59 were diagnosed as pulmonary 
tuberculosis including pleural effusion. 
Of the 59 cases  
 
Male cases
Female cases
Male child
Female child
 
 
The prevalence of pulmonary tuberculosis in the HIV positive cases was 
8.4%.   (59 out of 707 cases)
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 wise distribution of the cases was as follows:
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The occupation  of these patients were as follows: 
 
 
Manual labourer 17 29% 
Agricultural labourer 4 7% 
House wife 8 14% 
Driver 4 7% 
Mill worker 3 5% 
Construction worker 5 8% 
Others like students, 
dhobi, sales man, 
business, veg. vendor, 
etc. 
18 30% 
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These patients presented with the following SYMPTOMS predominantly. 
 
 
SYMPTOMS 
CASES IN 
NUMBER 
PERCENTAGE 
Fever 59 100% 
Cough 57 96.6% 
Weight loss 45 76.3% 
Weakness/ lassitude 22 37.3% 
Hemoptysis 2 3.4% 
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Sputum AFB results were as follows:
Total no. of cases : 59 
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WHO staging of these 59 cases were 
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The Sputum AFB status in correlation to the CD4 count was as follows:
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 THE CHEST X RAY FINDINGS IN CORRELATION WITH CD4 
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 Of the 59 cases, 23 cases were on 
TOTAL NO. OF CASES ON HAART = 23
CHEST X RAY FINDINGS IN HIV POSITIVE PATIENTS ON HAART WHO 
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DISCUSSION 
 
 
 
     The study conducted showed out of 707 cases of HIV disease, 
59 cases were found to have been suffering from pulmonary tuberculosis, 
ie 8.4% of HIV positive cases. This is in support of the study conducted 
by Neeraj Raizada  et al in 2008 which showed a prevalence varying 
between 1& to 13.8 % in various states of India.
 (24) 
The observation also 
correlates with the study conducted by N. Kumarasamy et al. in 2005, 
which showed prevalence of HIV among patients with radiologic or 
bacteriologic confirmation of TB in India ranges from 2.8 to 9.4  
per cent.
(25)
 
 
     The study conducted out of 59 cases 63% were male, 36% were 
female and 1% was female child, showing a increased prevalence of 
HIV/PTB smong male population. This study correlated with the study of 
HIV seroprevalence was higher among male tuberculosis patients than 
female tuberculosis patients by Neeraj Raizada et al in 2008. 
(25) 
 
     From the study conducted, it was observed that the age groups 
between 21 to 40 years were commonly affected from HIV and PTB 
ie.75%. This observation correlated with the study conducted by C.N. 
Deivanayagam et al. - 74.1%. 
(26)
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 The average age affected by the disease was 37.1, which indicates that, 
the economically productive group of the population is at the greatest risk 
of tuberculosis HIV co-infection, thereby causing a heavy socioeconomic 
loss by and large. 
     With regard to the occupation, the manual labourers, agricultural 
labourers and house wives, drivers, construction workers and mill 
workers constituted 70% of HIV/TB cases in this region. This may be 
attributed to poor literacy, poverty, malnutrition, overcrowding, lack of 
knowledge of safe sexual practice, lack of knowledge of personal 
protection etc. 
     Analysis of the symptoms showed that all the cases were suffering 
from fever, the fever being low grade, intermittent in most cases. 96.6% 
cases had cough, 76.3% cases had weight loss, 37.3% cases had weakness 
and lassitude and 3.4% had hemoptysis. This correlated with the studies 
of Zuber Ahmad et al. 
(27)
 Purohit et al 
(28)
, Mohanty et al 
(29),
 and Gupta et 
al 
(30)
, fever was the most common complaint along with cough and 
anorexia and weight loss.  
 
     Sputum AFB was positive in 26 cases and was negative in 33 cases 
(44% and 56% respectively). This correlated with the study of E. J. Peters 
et al. 
(31)
 whose observation was 40%and 53% repectively. This supports 
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the findings of Sputum AFB positivity of 44 % by S. Rajasekaran et al. 
(32) 
     The radiological findings were infiltrations in 47% of cases, cavity in 
22% of cases, consolidation in 14% of cases, pleural effusion in 12% of 
cases, hilar adenopathy in 3% of cases and military mottling in 2% of 
cases. It was observed that a total of 49 out of 59 cases (83%) presented 
as infiltrations, cavities or consolidation. This correlated with the studies 
of Soumya Swaminathan et al 
(33)
 and Zuber Ahmad et al. 
(34) 
 
The WHO staging of the cases under study were that, in stage III 
there were 50 cases and in stage IV, there were 9 cases.  
 
The CD4 counts in these cases studied were as follows. Among the 
59 cases, 26 cases were sputum AFB positive and 33 cases were negative. 
Among the Sputum AFB positive cases, 16 cases had CD4 count less 
than 200; rest 10 cases were above 200. In the Sputum AFB negative 
cases, 19 were found to have CD4 count less than 200 and 10 cases above 
200. 
 
     The correlation between the CD4 counts and the radiological 
manifestations were that at lower CD4 counts < 200 the pleural effusion 
and hilar adenopathy – 8 cases; consolidation 6 cases, cavity  3 cases and 
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infiltrations 20 cases. Whereas in cases with CD4 count >200, the 
findings were that 1 case of pleural effusion, 2 cases of consolidation, 8 
cases of infiltrations and cavity seen in 10 cases.  
 
     In patients who have CD4 counts of 200 or more, chest X-Ray 
findings were  upper lobe cavitation .In cases who have CD4 count fewer 
than 200/mm3, mediastinal adenopathy, miliary patterns , diffuse 
pulmonary infiltrations ,military mottling , absence of pulmonary 
cavitation   and combined pulmonary and extrapulmonary disease are 
seen more often in patients with lower CD4 count. This observation 
correlated with the study by M. Hajiabdolbagi et al. 
(35)
, Pearlman DC et 
al 
(36)
, and Jones BE et al 
(37)
 
 
     It was also observed that out of 59 HIV/PTB cases, 23 cases (15 male 
and 8 female cases) were on HAART already, which meant that these 
patients developed pulmonary tuberculosis during the period they were 
on treatment for HIV disease. Of these 23 cases 79% of cases (18 cases) 
were cavities and infiltrations. With correlation to the CD4 count, it was 
observed that there were 10 out of 11 cases of CD4 count less than 200 
presenting as infiltrations and 4 out of 6 cases presented as cavities with 
CD4 count above 200. Post-HAART TB had the similar manifestations of 
tuberculosis occurring in advanced immune suppression. This is 
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supported by the previous Indian studies of Rajasekaran et al and S. 
Swaminathan et al. (
38, 39, and 40)
 Higher Sputum smear negative pulmonary 
TB, higher proportion of extra-pulmonary TB  and increased  frequency 
of disseminated TB  were observed in this study. The reason for the 
development of cavitatory lesions may be that in these cases immune 
reconstitution inflammatory syndrome (IRIS) may be responsible for the 
lesion. The reason for the development of PTB during HAART is that, 
HIV-induced depression of cellular immunity increases the susceptibility 
of individuals to develop tuberculosis through either reactivation of latent 
infection or rapid progression of a recent infection. The location and 
extent of tuberculosis in HIV-infected individuals depend largely on the 
degree of the immunosuppression, with an increased frequency of 
extrapulmonary and disseminated tuberculosis and lower field infiltrative 
pulmonary tuberculosis in the more severely immunocompromised. 
 Out of 23 cases only 8 cases were having a CD4 count of more than 200; 
rest was below 200. The likeliest explanation is that a proportion of HIV-
infected patients, especially those with low nadir CD4 cell counts, have 
poor CD4 cell responses to HAART that may in some be related to lack 
of viral suppression. These patients are likely to retain a chronically 
heightened risk of TB. 
(41,  42,  43.) 
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    Manifest - TB in HIV can also be a part of immune reconstitution 
inflammatory syndrome (IRIS). It is defined as transient worsening or 
appearance of new symptoms, signs or radiographic manifestations after 
initiation of highly active antiretroviral therapy (HAART). The incidence 
of IRIS in TB alone was 2%, with HIV co-infection was 7% and in those 
started on HAART was 36% as reported in a study by Narita et al
 (44)
. The 
most common symptom of TB presenting as IRIS is fever along with 
worsening infiltrates on chest x-ray. Other manifestations include 
enlargement of the affected lymph nodes and liquefaction or appearance 
of new lymph nodes, pleural and pericardial effusion, ascites, central 
nervous system (CNS) lesions and visceral lesions. Risk factors for TB 
presenting as IRIS include early initiation of antiretroviral therapy (ART) 
within 2 months of starting antituberculous therapy (ATT), low CD4, 
presence of extrapulmonary TB especially of the CNS, disseminated TB 
and high viral load. The extent of immune reconstitution resulting from 
HAART is greatest during the first 2 years of treatment. Long-term 
HAART confers a greater reduction in TB risk than previously reported 
and HAART may, therefore, contribute more to TB control in low-
income countries than previously estimated. 
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     It was also observed that there were 8 HIV cases presently diagnosed 
as suffering from PTB; these patients were treated for tuberculosis earlier. 
These cases were started on CAT II ATT as per the RNTCP guidelines. 
To the surprise it was noted that out of 8 cases, 6 were cavities and 
infiltrations and out of the 6 cases 5 were sputum AFB positive.  
These five cases can be, cases have an increased risk of developing 
drug resistance or MDR TB. The incidence of development of MDR TB 
in HIV patients is high compared to non HIV patients. The reasons may 
be a) poor absorption of the drug in the gut. b) Poor compliance to the 
drug either ATT or ART. c) Drug interactions of ARTdrugs with ATT 
drugs like, Rifampicin increases the cytochrome P 450 enzyme activity 
thereby causing decreased availability of PIs and NNRTIs
 (45). 
. The risk 
of drug resistance to ATT has not been proved in cases of HIV/TB cases. 
There are varying studies regarding this. In study conducted by C N 
Deivanayagam et al, it has been concluded that the amplifying and 
accelerating influence of HIV disease and delayed recognition of PTB 
among the HIV patients may contribute to the development of MDR TB 
among the HIV infected patients.
 (46)
 In a study by Akksilp S et al. it was 
found that HIV incidence was found to be high among the MDR TB 
patients, but not an independent risk factor for MDR TB. 
(47)
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      Hence apart from the diagnosis and management of HIV/TB cases, 
measures must be taken to identify the latent tuberculous infection at the 
earliest and treat. 
ATT drug sensitivity test has to be carried out in all HIV PTB cases, 
to know the drug sensitivity pattern and to treat these patients effectively, 
in order to prevent MDR TB in HIV patients and also prevent the spread 
of the MDR TB in the community.  
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CONCLUSION 
 
 Pulmonary Tuberculosis is one of the commonest opportunistic 
infection among the HIV positive individuals. 
 The prevalence of Pulmonary tuberculosis is more in male than in 
female population of HIV positive individuals.  
 Pulmonary Tuberculosis occurs early in the HIV infection even before 
the CD 4+ count falls to very low levels 
 Manual labourers, agricultural labourers, etc of lower socioeconomic 
state with low literacy rate were more commonly affected by HIV-
PTB co - infection.  
 Fever, cough and loss of appetite and loss of weight were  most 
common symptoms observed in HIV with Pulmonary TB co-infection/ 
individually. 
 Sputum AFB was negative in tuberculosis  presentations like hilar 
adenopathy, military mottling, pleural effusion etc. 
 The radiological findings of infiltration were most common 
presentation, cavitatory lesions, consolidation, and pleural effusion etc 
follows. in that order. Lower the CD4 count, more were the incidence 
of pulmonary infiltration, pleural effusion, hilar adenopathy and 
military mottling. The cavitatory lesions manifest at higher CD4 
counts. 
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 Sputum AFB negativity was more commonly seen in pulmonary 
tuberculosis of  seropositive HIV individuals.  
 Immune reconstitution inflammatory syndrome is seen in patients 
HAART wherein the latent TB or reinfection are seen.  
 Treatment of TB can prolong the life and improve the quality of life 
for HIV-positive people. 
 Knowledge of the clinico-radiological spectrum of tuberculosis and 
co-existing opportunistic infections is absolutely necessary for the 
early detection of the disease and initiating the treatment. 
 As the rate of rise of PTB is increasing in the HIV endemic regions, 
improved diagnostic testing, especially directed towards early 
diagnosis of PTB and for the diagnosis of latent Tuberculous infection 
is the need of the day.  
 The possibility of the occurrence of MDR TB has to be considered in 
cases in whom drug compliance is poor. These patients must be 
motivated with positive approach for regular treatment and must be 
monitored closely. 
 Facilities for ATT drug susceptibility testing must be done at the time 
of diagnosis of PTB so that the ATT regimen can be modified 
accordingly. 
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DEPARTMENT OF GENERAL MEDICINE, COIMBATORE MEDICAL COLLEGE . 
STUDY OF CLINICO-DIAGNOSTIC PATTERN OF PULMONARY TUBERCULOSIS AMONG HIV 
PATIENTS 
Informed consent form for prospective participants 
 
Principal Investigator: Dr BALAJI. S, Junior Resident. 
Research Guide: Prof. Dr. M. RAVEENDRAN, MD UNIT CHIEF, Medical Unit – IV. 
Organization:  Department of Medicine, Coimbatore Medical College Hospital. 
 
This informed consent form has two parts 
PART – I INFORMATION SHEET (to share the information about the research with you) 
PART – II CERTIFICATE OF CONSENT (for signatures if you agree to take part) 
(You will be given a copy of the full informed consent form.) 
 
PART – I INFORMATION SHEET 
I, Dr. S. BA.AJI, Junior resident in Dept of Medicine, invite you to join as participant in my research on 
manifestations of pulmonary tuberculosis in HIV patients, which is one of the serious infectious diseases 
in our country. I am going to give you information and invite you to be part of this research. You do not 
have to decide today whether or not you will participate in the research. Before you decide, you can talk 
to anyone you feel comfortable with about the research.  
 
There may be some words that you do not understand. Please ask me to stop as we go through the 
information and I will take time to explain.  If you have questions later, you can ask them of me, the 
study doctor or the staff. 
 
Tuberculosis is the commonest opportunistic infection occurring among HIV positive persons in India 
and it is estimated that 60-70% of HIV positive persons will develop tuberculosis in their lifetime.. 
HIV infection has increased the burden of tuberculosis, especially in populations where HIV has become 
common, and where the prevalence of tuberculosis infection is high.  
We are doing this research to learn the correlation of the CD 4 count and the manifestations of 
tuberculosis in the HIV positive patients and to acquire knowledge about the disease manifestations in 
our region so as to plan for early identification of the disease and better, management. 
In this study you will have to answer questions regarding your illness, undergo a physical examination, 
give blood for tests, and undergo x ray examination and sputum examination. 
 
 
 
 
83 
 
You are being selected because we are inviting all HIV positive patients with chest symptoms 
suggestive of pulmonary tuberculosis attending our medical op, chest clinic/ HIV clinic to enroll in the 
study 
 
Your participation in this research is entirely voluntary. It is your choice whether to participate or not. 
Whether you choose to participate or not, all the services you receive at this clinic will continue and 
nothing will change. You may change your mind later and stop participating even if you agreed earlier. 
 
You will have to give details regarding your age, duration of disease, family history of the disease, any 
symptoms you are having at present, your past medical problems, surgeries and current medications. A 
doctor will examine you to look for any problems. Your height and weight will be recorded. All the data 
will be recorded in a proforma. Ten ml of blood will be drawn for doing various laboratory tests to know 
about the status of your disease. Any excess sample will be destroyed immediately after the laboratory 
tests are completed. Taking the blood sample will produce some pain and there may be slight redness 
at the site of puncture for a day or two. . You will be subjected to X ray chest examination and you will 
give the sputum expectorated for examination. There will be no significant risk on exposure to X ray 
radiation and also no discomfort in collecting the sputum sample for examination. 
 
On the first day you will be asked about your problems, a doctor will check you up. You will also have to 
give the blood. You will be taken the x ray chest and your sputum will be collected twice i.e. on two 
consequent days. You will be asked to collect the early morning sputum expectorated out after self 
inducing a cough.  
 
In total you will have to visit twice or thrice for the research purpose. By participating in this research it is 
possible that you may experience some discomfort as each of your visits will take longer than your 
usual bi-weekly follow up visits and will involve needle pricks to give blood samples. 
 
If you participate in this research you will be having a thorough check up, which may reveal some 
unidentified problems in you. We will promptly start the treatment for them. Also by participating you are 
providing valuable data that will help doctors understand this disease better and ultimately serve the 
patients in a better way. 
 
We will not be providing any money for participating in this research; you may incur more expense since 
you will have to visit the hospital more frequently. 
 
It is possible that if others in the community are aware that you are participating in this research, they 
may ask you questions. We will not be sharing the identity of those participating in the research with 
anyone. The information that we collect from this research project will be kept confidential. Information 
about you that will be collected during the research will not be identified by your name but by a number. 
Only the researchers will know what your number is and they will lock that information up with a lock 
and key. It will not be shared with or given to anyone except my research guide. 
 
The knowledge that we get from doing this research will be shared with you before it is made widely 
available to the public. Confidential information will not be shared. There will be small meetings in the 
community and these will be announced. After these meetings, we will publish the results in order that 
other interested people may learn from our research 
 
You do not have to take part in this research if you do not wish to do so. You may also stop participating 
in the research at any time you choose. It is your choice and all of your rights will still be respected. 
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If you have any questions you may ask them now or later, even after the study has started. If you wish 
to ask questions later, you may contact  
 
Dr S. BALAJI,                   Prof .Dr. M. RAVEENDRAN, MD. 
Junior Resident,      Unit Chief, Medical Unit –IV, 
Dept of Medicine,                   Dept of Medicine, 
Coimbatore Medical College Hospital  Coimbatore Medical College Hospital, 
Coimbatore – 18.     Coimbatore- 18. 
Phone –99945 47945.     
 
 
This proposal has been reviewed and approved by the Ethics Committee of Coimbatore Medical 
College Hospital which is a committee whose task it is to make sure that research participants are 
protected from harm. 
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PART – II CERTIFICATE OF CONSENT 
 
I have been invited to participate in research on pulmonary manifestations of HIV. I understand that it 
will involve answering a detailed questionnaire, undergoing a thorough physical exam, giving blood 
samples, taking X ray chest giving sputum samples for examination and two or three follow-up visits. I 
have been informed that the risks are minimal and may include only slight pain and redness at sight of 
needle prick. And no significant risk of exposure to X ray radiation or no discomfort in collecting the 
sputum samples. I am aware that there may be no benefit to me personally and that I will not be 
compensated monetarily. I have been provided with the name of a researcher who can be easily 
contacted using the number and address I was given for that person. 
 
I have read the foregoing information or it has been read to me. I have had the opportunity to ask 
questions about it and any questions I have asked have been answered to my satisfaction. I consent 
voluntarily to participate as a participant in this research and understand that I have the right to withdraw 
from the research at anytime without in anyway affecting my medical care. 
 
Name of the participant:  ________________________________________________ 
 
Signature of the participant: ________________________________________________ 
 
Date:    ________________________________________________ 
     (Day/Month/Year) 
 
If illiterate 
A literate witness must sign (if possible, this person should be selected by the participant and must have 
no connection to the research team) 
I have witnessed the accurate reading of the consent form to the potential participant, translated to his 
mother tongue, and the individual has had opportunity to ask questions. I confirm that the individual has 
given consent freely. 
Name of witness:  _________________________ AND        Thumb print of 
participant 
Signature of witness: _________________________ 
Date:   _________________________ 
   (Day/Month/Year) 
 
I have accurately read or witnessed the accurate reading of the consent form to the potential participant, 
and the individual has had the opportunity to ask questions. I confirm that the individual has given 
consent freely. 
Name of the researcher:  ______________________________________ 
Signature of the researcher: ______________________________________ 
Date:    ______________________________________ 
    (Day/Month/Year) 
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PROFORMA 
 
1. NAME                                          AGE                                       SEX 
2. OCCUPATION                                                                            MONTHLY 
INCOME 
3. HEIGHT                                                                                        WEIGHT 
4. ADDRESS 
 
5. CLINICAL PROFILE 
FEVER                                        COUGH                    HEMOPTYSIS                        
LOSS OF WEIGHT                    LASSITUDE/ WEAKNESS                
H/O PRIOR ATT 
6. SPUTUM AFB STATUS 
7. CHEST X RAY FINDINGS 
INFILTRATIONS 
CAVITY 
CONSOLIDATION 
PLEURAL EFFUSION 
HILAR ADENOPATHY 
MILIARY MOTTLING 
OTHERS 
8. BLOOD INVESTIGATIONS 
TC                                                        DC                                       ESR                                                   
HB% 
SUGAR                                               UREA 
S.CREATININE 
LFT S. BILIRUBIN                            SGOT                                  SGPT                                                  
ALP 
9. CD4 COUNT 
10. ATT CATEGORY                             CAT I                                   CAT II 
11. DATE OF START OF                      A. ATT                                  B. ART 
12. OTHERS 
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